These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 38500874)

  • 1. Effects of tumor necrosis factor-alpha inhibitors on lipid profiles in patients with psoriasis: a systematic review and meta-analysis.
    Su L; Xu C; Huang H; Zhang P; Wang J; Ouyang X; Yang X; Ye J
    Front Immunol; 2024; 15():1354593. PubMed ID: 38500874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.
    Dommasch ED; Abuabara K; Shin DB; Nguyen J; Troxel AB; Gelfand JM
    J Am Acad Dermatol; 2011 Jun; 64(6):1035-50. PubMed ID: 21315483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2022 May; 5(5):CD011535. PubMed ID: 35603936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis.
    Xie W; Xiao S; Huang H; Zhang Z
    Front Immunol; 2022; 13():847160. PubMed ID: 35300336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
    Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
    Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.
    Ryan C; Leonardi CL; Krueger JG; Kimball AB; Strober BE; Gordon KB; Langley RG; de Lemos JA; Daoud Y; Blankenship D; Kazi S; Kaplan DH; Friedewald VE; Menter A
    JAMA; 2011 Aug; 306(8):864-71. PubMed ID: 21862748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor inhibitors in psoriasis: an update.
    Kerdel FA; Strober BE
    Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S31-6. PubMed ID: 24979543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of TNF-alpha antagonists for plaque-type psoriasis: a systematic review and graphical presentation].
    Levy-Roy A; Porcher R; de Fonclare AL; Morel P; Dupuy A
    Ann Dermatol Venereol; 2009 Apr; 136(4):315-22. PubMed ID: 19361697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNF agents for paediatric psoriasis.
    Sanclemente G; Murphy R; Contreras J; García H; Bonfill Cosp X
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010017. PubMed ID: 26598969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation.
    Tikhonova IA; Yang H; Bello S; Salmon A; Robinson S; Hemami MR; Dodman S; Kharechko A; Haigh RC; Jani M; McDonald TJ; Hoyle M
    Health Technol Assess; 2021 Feb; 25(8):1-248. PubMed ID: 33555998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infections associated with the use of tumor necrosis factor-α inhibitors in psoriasis.
    Tan X; Balkrishnan R; Feldman SR
    J Drugs Dermatol; 2013 Mar; 12(3):e41-5. PubMed ID: 23545925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of curcumin-containing supplementations on inflammatory markers and lipid profiles in patients with chronic kidney diseases: a systematic review and meta-analysis of randomized controlled trials.
    Futuhi F; Naghibzadeh Tahami A; Azmandian J; Saber A
    J Complement Integr Med; 2022 Sep; 19(3):531-541. PubMed ID: 35649583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review.
    Brezinski EA; Follansbee MR; Armstrong EJ; Armstrong AW
    Curr Pharm Des; 2014; 20(4):513-28. PubMed ID: 23565632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.